- Conditions
- Insomnia
- Interventions
- E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-05190457 or Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- PER977, Placebo, Heparin Sodium
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cardiovascular
- Interventions
- AMG 529, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Type 2 Diabetes
- Interventions
- Mitoglitazone, Pioglitazone, Placebo
- Drug
- Lead sponsor
- Metabolic Solutions Development Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
- Conditions
- Falls
- Interventions
- Individualized multifactorial intervention for community-living high-risk older adults, Health professional education program about fall prevention
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
- Interventions
- CD30.CAR-T, Fludarabine, Bendamustine
- Drug
- Lead sponsor
- Tessa Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2037
- U.S. locations
- 5
- States / cities
- Duarte, California • Chicago, Illinois • Philadelphia, Pennsylvania + 2 more
- Conditions
- HIV Infections
- Interventions
- CD4 Antigens
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg, GW642444 25mcg, GW642444 50mcg, placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 49
- States / cities
- Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more
- Conditions
- HIV-1-Infection
- Interventions
- Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
- Conditions
- Excess Abdominal Fat
- Interventions
- UltraShape
- Device
- Lead sponsor
- Syneron Medical
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Chestnut Hill, Massachusetts • Edina, Minnesota
- Conditions
- Alzheimer Disease
- Interventions
- NTRX-07, Placebo
- Drug
- Lead sponsor
- NeuroTherapia, Inc.
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Gates Mills, Ohio
- Conditions
- Pemphigus Vulgaris (PV)
- Interventions
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more
- Conditions
- Alzheimer's Disease
- Interventions
- RVT-101 35 mg tablets
- Drug
- Lead sponsor
- Axovant Sciences Ltd.
- Industry
- Eligibility
- 50 Years to 86 Years
- Enrollment
- 1,099 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo)
- Biological
- Lead sponsor
- Nielsen BioSciences, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Moderate to Severe Nasolabial Folds
- Interventions
- JUVEDERM VOLIFT® XC, Control
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
- Conditions
- Healthy Volunteer Study
- Interventions
- Xenon gas inhalation
- Drug
- Lead sponsor
- General Biophysics LLC
- Industry
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- Concizumab, Eptacog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa
- Conditions
- Prematurity, Very Low Birth Weight
- Interventions
- Silver Alginate
- Device
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- Up to 72 Hours
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease
- Interventions
- Afegostat tartrate
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 7 more
- Conditions
- Advanced Solid Tumors
- Interventions
- palifosfamide-tris, Normal Saline
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Houston, Texas • San Antonio, Texas